Humana

The stool-based test was approved by US regulators in 2014 and included as an A-rated service in the US Preventive Services Task Force's colorectal cancer screening guidelines earlier this year.

The deal suggests the company is making steady progress toward its goal of signing coverage deals with all major private payors by year end.

The case suggests that the Affordable Care Act's provisions on coverage of preventive services may add another layer of complexity to already strained relations.

The company estimates Humana owes it upwards of $800,000 in payment for nearly 4,700 Cologuard tests it has performed since October 2014.

This article has been updated to clarify that Genomic Health has submitted research data on Oncotype DX testing in the DCIS population to the San Antonio Breast Cancer Symposium. The abstract has not yet been accepted for presentation. Originally published Aug. 5.

The contract will expand coverage for MammaPrint by more than 17 million lives, according to Agendia.

Already a pioneer in incorporating pharmacogenetic testing into its PBM programs, Medco's decision to buy DNA Direct signals its intent to be a "one-stop shop" for payors and employers interested in using genetically guided medicine to make healthcare more efficient and lower costs.

Data from two national insurers, Humana and Aetna, shows that around 20 percent of requests for the test do not meet requirements for testing under their policy. A United Healthcare official has cited competitors' data suggesting that as much as 80 percent of requests for Myriad's BRCA test are withdrawn after pre-certification and genetic counseling procedures are conducted.

Paired Ends

Premium

Jonathan Lord, Lisa Wise, James O'Leary, Paul Keim

People in the News

Jack Lord is named president and CEO of Navigenics, while Celera has a new CFO, and Patrick Terry joins the board of directors of TcLand Expression, plus more.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.